Patents by Inventor David Frazier Jarrard

David Frazier Jarrard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Image analysis of epithelial component of histologically normal prostate biopsies predicts the presence of cancer
    Patent number: 11721021
    Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: August 8, 2023
    Assignees: Wisconsin Alumni Research Foundation, The Medical College of Wisconsin, Inc.
    Inventors: David Frazier Jarrard, Bing Yang, Peter LaViolette
  • IMAGE ANALYSIS OF EPITHELIAL COMPONENT OF HISTOLOGICALLY NORMAL PROSTATE BIOPSIES PREDICTS THE PRESENCE OF CANCER
    Publication number: 20220414878
    Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.
    Type: Application
    Filed: August 25, 2022
    Publication date: December 29, 2022
    Applicants: Wisconsin Alumni Research Foundation, The Medical College of Wisconsin, Inc.
    Inventors: David Frazier Jarrard, Bing Yang, Peter LaViolette
  • UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER
    Publication number: 20220307091
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Application
    Filed: June 10, 2022
    Publication date: September 29, 2022
    Inventors: David Frazier Jarrard, Bing Yang
  • Image analysis of epithelial component of histologically normal prostate biopsies predicts the presence of cancer
    Patent number: 11449987
    Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 20, 2022
    Assignees: Wisconsin Alumni Research Foundation, The Medical College of Wisconsin, Inc.
    Inventors: David Frazier Jarrard, Bing Yang, Peter LaViolette
  • Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
    Patent number: 11377694
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: July 5, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: David Frazier Jarrard, Bing Yang
  • UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER
    Publication number: 20210404018
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject. The method includes (a) obtaining genomic DNA from the human subject and (b) determining methylation status in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2, WNT2, EXT1, and SPAG4, wherein methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 30, 2021
    Inventors: David Frazier Jarrard, Bing Yang
  • Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
    Patent number: 11130998
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: September 28, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David Frazier Jarrard, Bing Yang
  • IMAGE ANALYSIS OF EPITHELIAL COMPONENT OF HISTOLOGICALLY NORMAL PROSTATE BIOPSIES PREDICTS THE PRESENCE OF CANCER
    Publication number: 20200202525
    Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Inventors: David Frazier Jarrard, Bing Yang, Peter LaViolette
  • Epithelial quantitation of histologically normal prostate tissue predicts the presence of cancer in tissue biopsies
    Patent number: 10598664
    Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial percentage of the tissue, wherein an epithelial percentage greater than 39% indicates the presence of prostate cancer or a prostate cancer field defect.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 24, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: David Frazier Jarrard, Bing Yang
  • UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER
    Publication number: 20180334723
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Application
    Filed: May 3, 2018
    Publication date: November 22, 2018
    Inventors: David Frazier Jarrard, Bing Yang
  • Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
    Patent number: 10131953
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: November 20, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David Frazier Jarrard, Bing Yang
  • UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER
    Publication number: 20180135136
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 17, 2018
    Inventors: David Frazier Jarrard, Bing Yang
  • EPITHELIAL QUANTITATION OF HISTOLOGICALLY NORMAL PROSTATE TISSUE PREDICTS THE PRESENCE OF CANCER IN TISSUE BIOPSIES
    Publication number: 20180136215
    Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial percentage of the tissue, wherein an epithelial percentage greater than 39% indicates the presence of prostate cancer or a prostate cancer field defect.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 17, 2018
    Inventors: David Frazier Jarrard, Bing Yang
  • UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER
    Publication number: 20140296355
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: David Frazier Jarrard, Bing Yang